Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Effect of Calycosin-7-O-β-D-Glucoside and its Synergistic Augmentation of Cisplatin-induced Apoptosis in SK-OV-3 Cells

Author(s): Jin-Zhi Huang, Liang-Liang Li, Xiao-Yu Tan, Zhao-Yi Wu, Dan-Wei Chen and Xin Luo*

Volume 28, Issue 26, 2022

Published on: 05 August, 2022

Page: [2161 - 2166] Pages: 6

DOI: 10.2174/1381612828666220610164100

Price: $65

Abstract

Objective: This study aims to examine the synergetic augmentation of calycosin-7-O-β-D-glucoside (CG) on cisplatin (CDDP) to induce apoptosis of human epithelial ovarian SK-OV-3 cancer cells.

Methods: The SK-OV-3 cells were divided into four groups: control, CDDP monotherapy, CG monotherapy, and combined CDDP and CG treatment. The cell counting kit-8 method detected cell proliferation at different times and under different treatments. Hoechst 33258 staining and annexin V-FITC/propidium iodide double staining methods were used to observe the apoptosis of the SK-OV-3 cells. The caspase-3 enzyme activity detection method, quantitative reverse transcription-polymerase chain reaction, and western blot were used to detect the apoptosis-related factors and the activities of the enzyme in SK-OV-3 cells.

Results: The inhibition rates of SK-OV-3 cell proliferation when exposed to 10 μM of CDDP, 50 μM of CG, and a combination of 10 μM of CDDP and 50 μM of CG were 23.2% ± 1.1%, 26.7% ± 2.0%, and 46.7% ± 1.3% after 48 h, respectively. Following the use of the drug combination, the apoptosis rate and caspase-3 enzyme activity were significantly higher than in the single-drug treatment group; the data differences were also significant (p < 0.05). At the protein and ribonucleic acid levels, CG significantly enhanced the effect of CDDP on p53, caspase-3, caspase-9, Bax, and Bcl-2.

Conclusion: In vitro, CG significantly increases the CDDP-induced apoptosis of the SK-OV-3 cells through the p53 pathway at the cellular level. In addition, using the drugs in combination reduces the toxicity and side effects caused by using CDDP alone.

Keywords: Calycosin-7-O-β-D-glucoside, epithelial ovarian cancer, SK-OV-3 cells, cisplatin, apoptosis, synergistic augmentation.

« Previous Next »
[1]
Albanaqi AA, Alotaibi KH. Epidemiology of ovarian cancer: an updated systematic review (2019-2021). Indo Am J Pharm Sci 2022; 09(03): 96-103.
[2]
Aust S, Pils D. Epithelial ovarian cancer - more data, more questions? Wien Med Wochenschr 2014; 164(21-22): 479-86.
[http://dx.doi.org/10.1007/s10354-014-0323-8] [PMID: 25392123]
[3]
Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: Current therapies and future perspectives - a review. J Ovarian Res 2019; 12(1): 103.
[http://dx.doi.org/10.1186/s13048-019-0579-0] [PMID: 31685032]
[4]
Vergote IB, Smith DC, Berger R, et al. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. Eur J Cancer 2017; 83: 229-36.
[http://dx.doi.org/10.1016/j.ejca.2017.06.018] [PMID: 28755607]
[5]
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol 2014; 6(5): 229-39.
[http://dx.doi.org/10.1177/1758834014544121] [PMID: 25342990]
[6]
Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician 2016; 93(11): 937-44.
[PMID: 27281838]
[7]
Tai J, Cheung S, Wu M, Hasman D. Antiproliferation effect of Rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro . Phytomedicine 2012; 19(5): 436-43.
[http://dx.doi.org/10.1016/j.phymed.2011.12.012] [PMID: 22325591]
[8]
Mondal A, Banerjee S, Bose S, et al. Garlic constituents for cancer prevention and therapy: From phytochemistry to novel formulations. Pharmacol Res 2022; 175: 105837.
[http://dx.doi.org/10.1016/j.phrs.2021.105837] [PMID: 34450316]
[9]
Hu H, Luo L, Liu F, et al. Anti-cancer and sensibilisation effect of triptolide on human epithelial ovarian cancer. J Cancer 2016; 7(14): 2093-9.
[http://dx.doi.org/10.7150/jca.16178] [PMID: 27877225]
[10]
Zhang LQ, Lv RW, Qu XD, Chen XJ, Lu HS, Wang Y. Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3 cells through the inhibition of the MAPK signaling pathway. Anal Cell Pathol (Amst) 2017; 2017: 8158254.
[http://dx.doi.org/10.1155/2017/8158254] [PMID: 28702312]
[11]
Li Q, Hu K, Tang S, Xu LF, Luo YC. Anti-tumor activity of tanshinone IIA in combined with cyclophosphamide against Lewis mice with lung cancer. Asian Pac J Trop Med 2016; 9(11): 1084-8.
[http://dx.doi.org/10.1016/j.apjtm.2016.09.003] [PMID: 27890369]
[12]
Xie J, Liu JH, Liu H, et al. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. BMC Cancer 2016; 16(1): 899.
[http://dx.doi.org/10.1186/s12885-016-2921-x] [PMID: 27863471]
[13]
Zhang DM. Effects of calycosin-7-O-β-D-glucoside on cell apoptosis in cervical cancer HeLa cells and expression of Bcl-2/Bax. Chinese Trad Herbal Drugs 2015; 46(10): 1498-502.
[14]
Cheng Y, Mo F, Li Q, et al. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. Mol Cancer 2021; 20(1): 62.
[http://dx.doi.org/10.1186/s12943-021-01355-1]
[15]
He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity. Cell Metab 2021; 33(5): 988-1000.e7.
[http://dx.doi.org/10.1016/j.cmet.2021.03.002] [PMID: 33761313]
[16]
Zhang C, Chen L, Peng D, et al. METTL3 and N6-Methyladenosine promote homologous recombination-mediated repair of DSBs by modulating DNA-RNA hybrid accumulation. Mol Cell 2020; 79(3): 425-442.e7.
[http://dx.doi.org/10.1016/j.molcel.2020.06.017] [PMID: 32615088]
[17]
Chen J, Wang Y, Zhao D, et al. Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharm Sin B 2021; 11(1): 143-55.
[http://dx.doi.org/10.1016/j.apsb.2020.07.011] [PMID: 33532186]
[18]
Mittica G, Ghisoni E, Giannone G, et al. PARP inhibitors in ovarian cancer. Recent Patents Anticancer Drug Discov 2018; 13(4): 392-410.
[http://dx.doi.org/10.2174/1574892813666180305165256] [PMID: 29512470]
[19]
Decio A, Cesca M, Bizzaro F, et al. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clin Exp Metastasis 2015; 32(7): 647-58.
[http://dx.doi.org/10.1007/s10585-015-9734-1] [PMID: 26185056]
[20]
Mezencev R. Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: The complex world of the platinum complex. Curr Cancer Drug Targets 2015; 14(9): 794-816.
[http://dx.doi.org/10.2174/1568009614666141128105146] [PMID: 25431081]
[21]
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]
[22]
Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol 2017; 34(6): 103.
[http://dx.doi.org/10.1007/s12032-017-0960-z] [PMID: 28444622]
[23]
Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat 2020; 49: 100671.
[http://dx.doi.org/10.1016/j.drup.2019.100671] [PMID: 31841768]
[24]
Redhu AK, Bhat JP. Mitochondrial glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase abrogate p53 induced apoptosis in a yeast model: Possible implications for apoptosis resistance in cancer cells. Biochim Biophys Acta, Gen Subj 2020; 1864(3): 129504.
[http://dx.doi.org/10.1016/j.bbagen.2019.129504] [PMID: 31862471]
[25]
Guo L, Xu Y, Zhou A, et al. A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance. Mater Sci Eng C 2020; 108: 110403.
[http://dx.doi.org/10.1016/j.msec.2019.110403] [PMID: 31923941]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy